TB 006
Alternative Names: Anti-TIM-3 monoclonal antibody; TB-006Latest Information Update: 11 Mar 2025
At a glance
- Originator TrueBinding
- Class Anti-inflammatories; Antidementias; Antifibrotics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease; Autistic disorder; Parkinson's disease
- Phase I Stroke
- Preclinical Amyotrophic lateral sclerosis; Glioblastoma
- No development reported COVID 2019 infections
Most Recent Events
- 11 Mar 2025 Phase-I clinical trials in Stroke (IV), prior to March 2025 (TrueBinding pipeline, March 2025)
- 11 Mar 2025 Preclinical trials in Amyotrophic lateral sclerosis in USA (Parenteral), prior to March 2025 (TrueBinding pipeline, March 2025)
- 11 Mar 2025 Preclinical trials in Glioblastoma in USA (Parenteral), prior to March 2025 (TrueBinding pipeline, March 2025)